Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Blood samples for metabolite analysis Clear all
Terminated Early Phase 1 Interventional Results available

L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia

NCT03542812
View directory record Official record
Conditions
Infant,Premature, Bronchopulmonary Dysplasia, Pulmonary Hypertension
Interventions
L-Citrulline
Drug
Lead sponsor
University of Utah
Other
Eligibility
14 Days to 3 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Sep 15, 2026, 2:33 AM EDT
Completed No phase listed Observational

ARV Concentrations in Hair

NCT02768779
View directory record Official record
Conditions
HIV
Interventions
Hair analysis
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 15, 2026, 2:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tissue-Specific Metabolic Reprogramming in Diabetic Complications

NCT01823406
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Euglycemic clamp (normal blood sugar clamp) for 4 hours, hyperglycemic clamp (elevated blood sugar to 300) for 4 hours
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 15, 2026, 2:33 AM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 15, 2026, 2:33 AM EDT
Completed No phase listed Observational

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

NCT04917744
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 15, 2026, 2:33 AM EDT
Recruiting Phase 2 Interventional

Study of 18F-FFNP Breast PET/MRI

NCT06086704
View directory record Official record
Conditions
Breast Cancer
Interventions
18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 15, 2026, 2:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects

NCT00316797
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
123-I INER
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Sep 15, 2026, 2:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 15, 2026, 2:33 AM EDT
Completed No phase listed Observational

Metabolomics for Biomarker Discovery in Children With EoE

NCT03107819
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Plasma and urine metabolomics
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
2 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 15, 2026, 2:33 AM EDT
Recruiting Not applicable Interventional

Personalized Perioperative Analgesia Platform (PPAP) for Pediatric Spine Fusion Surgery (sIRB)

NCT05367609
View directory record Official record
Conditions
PPAP, Spine Fusion
Interventions
Preoperative Genotyping
Diagnostic Test
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
10 Years to 21 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • St. Petersburg, Florida • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 15, 2026, 2:33 AM EDT
Completed No phase listed Observational

Genetics of Fatty Liver Disease in Children

NCT01966627
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
ogtt, genotyping, abdominal and liver magnetic resonance imaging, stool sample, liver biopsy
Other
Lead sponsor
Yale University
Other
Eligibility
7 Years to 18 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 15, 2026, 2:33 AM EDT
Not yet recruiting No phase listed Observational

Methadone Dose Monitoring With a Remote Medication Monitor

NCT06837571
View directory record Official record
Conditions
Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions
Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
Diagnostic Test · Drug · Device
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 15, 2026, 2:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

NCT01093573
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
midostaurin, azacitidine, bone marrow aspiration, mutation analysis, Pharmacokinetic study
Drug · Other
Lead sponsor
Brenda Cooper, MD
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Cleveland, Ohio • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 15, 2026, 2:33 AM EDT
Terminated No phase listed Observational

Collection of Blood in Studying Metabolites in Patients With Prostate Cancer

NCT03485794
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 15, 2026, 2:33 AM EDT
Active, not recruiting No phase listed Observational

Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)

NCT02978118
View directory record Official record
Conditions
Carcinoma, Renal Cell, Carcinoma, Urothelial
Interventions
Immune cell and CTC detection procedures
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 15, 2026, 2:33 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
View directory record Official record
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 15, 2026, 2:33 AM EDT
Recruiting No phase listed Observational

Assessment of Methadone Dose Taken

NCT05981573
View directory record Official record
Conditions
Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions
Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
Diagnostic Test · Drug · Device
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 15, 2026, 2:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 15, 2026, 2:33 AM EDT